1 – 10 of 186
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
(
- Contribution to journal › Article
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
(
- Contribution to journal › Article
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
-
Mark
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
(
- Contribution to journal › Article
-
Mark
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8) : a prospective, multicentre, open-label, randomised, phase 3a trial
(
- Contribution to journal › Article
-
Mark
Future needs for continuing innovation in hemophilia : improving outcomes for individuals of all severities, including women and those in resource-constrained regions
(
- Contribution to journal › Scientific review